Focused On-demand Library for COUP transcription factor 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

P10589

UPID:

COT1_HUMAN

Alternative names:

COUP transcription factor I; Nuclear receptor subfamily 2 group F member 1; V-erbA-related protein 3

Alternative UPACC:

P10589

Background:

COUP transcription factor 1, also known as Nuclear receptor subfamily 2 group F member 1, plays a pivotal role in gene expression regulation. It binds to the ovalbumin promoter, stimulating transcription initiation in conjunction with S300-II. This protein's ability to bind both direct repeats and palindromes of the 5'-AGGTCA-3' motif showcases its versatility in gene regulation.

Therapeutic significance:

Linked to Bosch-Boonstra-Schaaf optic atrophy syndrome, a disorder marked by optic atrophy, developmental delay, and intellectual disability, COUP transcription factor 1's study could lead to novel therapeutic avenues. Understanding its role in cerebral visual impairment offers a promising pathway for targeted treatment strategies.